Published in AIDS Weekly, February 28th, 2005
"Atazanavir is the first once-daily protease inhibitor for the treatment of HIV-1 infection and should be used only in combination therapy, as part of a highly active antiretroviral therapy (HAART) regimen.
"In addition to being the most potent protease inhibitor in vitro, atazanavir has a distinct cross-resistance profile that does not confer resistance to other protease inhibitors. However, resistance to other protease inhibitors often confers clinically relevant resistance to atazanavir," researchers in the United States report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.